PortfoliosLab logoPortfoliosLab logo
RBRK vs. UTHR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

RBRK vs. UTHR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rubrik, Inc. (RBRK) and United Therapeutics Corporation (UTHR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RBRK achieves a -6.21% return, which is significantly lower than UTHR's 11.79% return.


RBRK

1D
-2.29%
1M
15.06%
YTD
-6.21%
6M
-19.49%
1Y
-26.74%
3Y*
5Y*
10Y*

UTHR

1D
-0.94%
1M
-3.58%
YTD
11.79%
6M
13.59%
1Y
67.18%
3Y*
33.59%
5Y*
25.53%
10Y*
17.20%
*Multi-year figures are annualized to reflect compound growth (CAGR)

RBRK vs. UTHR - Yearly Performance Comparison


2026 (YTD)20252024
RBRK
Rubrik, Inc.
-6.21%17.01%69.33%
UTHR
United Therapeutics Corporation
11.79%38.09%48.88%

Correlation

The correlation between RBRK and UTHR is -0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.09

Correlation (All Time)
Calculated using the full available price history since Apr 25, 2024

0.06

The correlation between RBRK and UTHR shifts across timeframes, from -0.09 (1 year) to 0.06 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

RBRK:

$14.61B

UTHR:

$25.71B

EPS

RBRK:

-$1.45

UTHR:

$27.00

PS Ratio

RBRK:

9.99

UTHR:

8.19

Total Revenue (TTM)

RBRK:

$1.42B

UTHR:

$3.17B

Gross Profit (TTM)

RBRK:

$1.15B

UTHR:

$2.74B

EBITDA (TTM)

RBRK:

-$275.30M

UTHR:

$1.75B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RBRK vs. UTHR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RBRK
RBRK Risk / Return Rank: 2525
Overall Rank
RBRK Sharpe Ratio Rank: 2424
Sharpe Ratio Rank
RBRK Sortino Ratio Rank: 2525
Sortino Ratio Rank
RBRK Omega Ratio Rank: 2626
Omega Ratio Rank
RBRK Calmar Ratio Rank: 2626
Calmar Ratio Rank
RBRK Martin Ratio Rank: 2525
Martin Ratio Rank

UTHR
UTHR Risk / Return Rank: 8686
Overall Rank
UTHR Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
UTHR Sortino Ratio Rank: 8787
Sortino Ratio Rank
UTHR Omega Ratio Rank: 8787
Omega Ratio Rank
UTHR Calmar Ratio Rank: 8989
Calmar Ratio Rank
UTHR Martin Ratio Rank: 8989
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RBRK vs. UTHR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rubrik, Inc. (RBRK) and United Therapeutics Corporation (UTHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


RBRKUTHRDifference
Sharpe ratioReturn per unit of total volatility

-1.78

Sortino ratioReturn per unit of downside risk

-3.02

Omega ratioGain probability vs. loss probability

0.97

1.37

-0.41

Calmar ratioReturn relative to maximum drawdown

-0.48

4.13

-4.61

Martin ratioReturn relative to average drawdown

-0.89

10.54

-11.43

RBRK vs. UTHR - Sharpe Ratio Comparison

The current RBRK Sharpe Ratio is -0.43, which is lower than the UTHR Sharpe Ratio of 1.36. The chart below compares the historical Sharpe Ratios of RBRK and UTHR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


RBRKUTHRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.43

1.36

-1.78

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.73

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.49

Sharpe Ratio (All Time)

Calculated using the full available price history

0.58

0.38

+0.19

Drawdowns

RBRK vs. UTHR - Drawdown Comparison

The maximum RBRK drawdown since its inception was -56.08%, smaller than the maximum UTHR drawdown of -93.18%. Use the drawdown chart below to compare losses from any high point for RBRK and UTHR.


Loading charts...

Drawdown Indicators


RBRKUTHRDifference

Max Drawdown

Largest peak-to-trough decline

-56.08%

-93.18%

+37.10%

Max Drawdown (1Y)

Largest decline over 1 year

-55.52%

-16.35%

-39.17%

Max Drawdown (3Y)

Largest decline over 3 years

-33.00%

Max Drawdown (5Y)

Largest decline over 5 years

-33.00%

Max Drawdown (10Y)

Largest decline over 10 years

-55.56%

Current Drawdown

Current decline from peak

-28.08%

-8.73%

-19.35%

Average Drawdown

Average peak-to-trough decline

-18.55%

-35.31%

+16.76%

Ulcer Index

Depth and duration of drawdowns from previous peaks

30.44%

6.39%

+24.05%

Volatility

RBRK vs. UTHR - Volatility Comparison

Rubrik, Inc. (RBRK) has a higher volatility of 20.05% compared to United Therapeutics Corporation (UTHR) at 5.15%. This indicates that RBRK's price experiences larger fluctuations and is considered to be riskier than UTHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RBRKUTHRDifference

Volatility (1M)

Calculated over the trailing 1-month period

20.05%

5.15%

+14.90%

Volatility (6M)

Calculated over the trailing 6-month period

49.12%

26.01%

+23.11%

Volatility (1Y)

Calculated over the trailing 1-year period

63.09%

49.84%

+13.25%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

64.32%

35.13%

+29.19%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

64.32%

35.07%

+29.25%

Dividends

RBRK vs. UTHR - Dividend Comparison

Neither RBRK nor UTHR has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

RBRK vs. UTHR - Financials Comparison

This section allows you to compare key financial metrics between Rubrik, Inc. and United Therapeutics Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


100.00M200.00M300.00M400.00M500.00M600.00M700.00M800.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026April
387.07M
781.50M
(RBRK) Total Revenue
(UTHR) Total Revenue
Values in USD except per share items

RBRK vs. UTHR - Profitability Comparison

The chart below illustrates the profitability comparison between Rubrik, Inc. and United Therapeutics Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

50.0%60.0%70.0%80.0%90.0%JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026April
80.6%
82.9%
Portfolio components
RBRK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rubrik, Inc. reported a gross profit of 311.78M and revenue of 387.07M. Therefore, the gross margin over that period was 80.6%.

UTHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a gross profit of 648.10M and revenue of 781.50M. Therefore, the gross margin over that period was 82.9%.

RBRK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rubrik, Inc. reported an operating income of -52.63M and revenue of 387.07M, resulting in an operating margin of -13.6%.

UTHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported an operating income of 325.80M and revenue of 781.50M, resulting in an operating margin of 41.7%.

RBRK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rubrik, Inc. reported a net income of -41.85M and revenue of 387.07M, resulting in a net margin of -10.8%.

UTHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a net income of 274.90M and revenue of 781.50M, resulting in a net margin of 35.2%.


Frequently Asked Questions


RBRK and UTHR have a correlation of -0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

RBRK has higher volatility (20.05%) compared to UTHR (5.15%). In terms of maximum drawdown, RBRK dropped -56.08% vs UTHR's -93.18%.

UTHR currently has the higher Sharpe Ratio (1.36 vs -0.43), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RBRK and UTHR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer